Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

INTRODUCTION: Multiple intravenous doses of ponezumab, an anti-amyloid antibody, were evaluated in subjects with mild-to-moderate Alzheimer's disease (AD). METHODS: In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 6...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Alzheimers Dement (N Y)
Asıl Yazarlar: Landen, Jaren W., Cohen, Sharon, Billing, Clare B., Cronenberger, Carol, Styren, Scot, Burstein, Aaron H., Sattler, Catherine, Lee, Jae-Hong, Jack, Clifford R., Kantarci, Kejal, Schwartz, Pamela F., Duggan, William T., Zhao, Qinying, Sprenger, Ken, Bednar, Martin M., Binneman, Brendon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2017
Konular:
Featured Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651443/
https://ncbi.nlm.nih.gov/pubmed/29067341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2017.04.003
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller